Do you ever wonder why the mortality of Americans (1.8%) is so high as compared to other countries?
Remdesivir studies with covid infections:
Findings
Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87–1·75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1·52 [0·95–2·43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.
But wait! There's more! Read some findings from a Ebola treatment trial. Just to give you a baseline of mortality of Ebola:
"In the largest Ebola outbreak in West Africa, there were 28,616 cases of Ebola virus disease and 11,310 deaths, for a death rate of 39.5% (low compared to historic death rates for Ebola Zaire)."
Now, to the data regarding remdesivir trialed for EBOLA:
Preliminary findings from an ongoing randomized controlled trial of four investigational Ebola virus treatments being conducted amid the outbreak in the Democratic Republic of Congo, or DRC, showed favorable results for two of the drugs, officials announced today.
The findings resulted in the discontinuation of two of the drugs in the trial, remdesivir (Gilead Sciences) and ZMapp (Mapp Biopharmaceutical). Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study, according to the officials from WHO and the National Institute of Allergy and Infectious Diseases.
According to Fauci (god on earth for some of you), the overall mortality rate among patients receiving ZMapp was approximately 49%. It was 53% for remdesivir, 29% for REGN-EB3 and 34% for mAb114. The results were “even more impressive” for patients with low viral loads who started treatment, Fauci added, with mortality rates of 24% for ZMapp, 33% for remdesivir, 6% for REGN-EB3 and 11% for mAb114."
So for those who cannot catch what they read, mortality of Ebola = 39.5%. Mortality of Ebola patients receiving remdesivir = 53%. In other words, your chances of dying increase with remdesivir administration. This failed miserably and they even stopped the remdesivir portion of the trial early.
Why was remdesivir repurposed for covid 19 if it increased chances of dying?? Side effects of remdesivir: ORGAN FAILURE including ACUTE RENAL (Kidneys) FAILURE. If your kindeys are not working, where does all of the fluid go??? INTO THE LUNGS. When you suffocate and have multiple organ failure, what do they chalk it up to?? WHY ARE THEY STILL GIVING REMDESIVIR FOR COVID19?? Stay out of hospitals that are still giving this medication. Choose Regen COV (made by Regeneron), stated above with the best outcomes for Ebola.
THIS IS A REPEAT OF RETROVIR (AZT) THAT FAILED FOR CANCER TREATMENT AND REPURPOSED FOR HIV.
KEEP YOUR HEAD ON A SWIVEL WHEN FEAR, MANIPULATION, AND DOMINATION ARE STRATEGIES OF CHOICE.
